Nektar Therapeutics
Clinical-stage biopharmaceutical company developing a pipeline of drug candidates.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $850m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 288 % | (90 %) | 33 % | (33 %) | (10 %) | (2 %) | 9 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 62 % | (332 %) | (227 %) | (445 %) | (240 %) | (127 %) | (113 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 57 % | (384 %) | (291 %) | (514 %) | (400 %) | (306 %) | (121 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 33 % | 379 % | 267 % | 393 % | 237 % | 127 % | 123 % |
Source: Company filings or news article
Related Content
Nektar Therapeutics, headquartered in San Francisco, CA, is a biopharmaceutical company specializing in the development of innovative therapies for cancer, autoimmune diseases, and chronic pain. The company operates in the healthcare sector, focusing on creating drugs that modulate the immune system to treat severe medical conditions. Nektar's primary clients include healthcare providers, hospitals, and research institutions that are involved in treating patients with complex diseases.
Nektar's business model revolves around research and development (R&D) of new drugs, followed by clinical trials to test their efficacy and safety. The company collaborates with other pharmaceutical firms to enhance its drug development process. For instance, Nektar has entered into a collaboration with SFJ Pharmaceuticals to develop Bempegaldesleukin, an IL-2 pathway agonist, for treating head and neck cancer. Additionally, they have partnered with Merck to combine Bempegaldesleukin with Merck's pembrolizumab for advanced studies in squamous cell carcinoma of the head and neck (SCCHN).
The company generates revenue through licensing agreements, milestone payments, and royalties from its developed drugs. Licensing agreements allow other companies to use Nektar's drug formulations in exchange for upfront payments and royalties on sales. Milestone payments are received when the company achieves specific goals in the drug development process, such as successful clinical trial phases or regulatory approvals.
Nektar's market includes the global pharmaceutical and biotechnology sectors, with a particular focus on oncology (cancer treatment) and immunology (immune system-related diseases). The company aims to address unmet medical needs by providing new treatment options that improve patient outcomes.
In summary, Nektar Therapeutics is a key player in the biopharmaceutical industry, leveraging its expertise in immune modulation to develop cutting-edge therapies for serious diseases. The company’s strategic collaborations and robust R&D pipeline position it well for future growth and innovation.
Keywords: Biopharmaceutical, Cancer, Autoimmune, Chronic Pain, Drug Development, Clinical Trials, Immunotherapy, Collaboration, Licensing, Revenue.
Tech stack
Investments by Nektar Therapeutics
Edit
